

## Special Issue

# mRNA Vaccines and Monoclonal Antibodies for Therapy

### Message from the Guest Editors

mRNA vaccines and monoclonal antibodies are emerging, promising treatments. mRNA vaccines contain messenger RNA (mRNA) which carries instructions to produce a specific protein. Once inside our body's cells, the mRNA acts as a blueprint to create a viral protein. Then, this protein induces specific antibodies. These antibodies persist for between 4 and 6 months, but immune cells remember how to defend against future infections. mRNA vaccines and monoclonal antibodies show promise in personalized medicine, thereby offering hope for improved outcomes and reduced side effects compared to those of traditional treatments. This Special Issue aims to provide insights into the safe, effective use of mRNA vaccines and of monoclonal antibodies. Novel articles, reviews, and preclinical studies that use human-relevant models or studies on humans are encouraged.

### Guest Editors

Dr. Giovanni Genovese

Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina 98124, Italy

Dr. Cristina Genovese

Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98124 Messina, Italy

### Deadline for manuscript submissions

closed (28 February 2025)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/204479](https://mdpi.com/si/204479)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).